Max Planck Innovation GmbH
Division of Max Planck Society
Latest From Max Planck Innovation GmbH
Cancer vaccine development is not the only R&D avenue being pursued by the Czech Republic-based biotech, SOTIO, which is aiming to become a fully-integrated biopharma company.
Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced July through August 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.